JPRN-UMIN000052251招募中Unknown
G-Lasta (pegfilgrastim) Subcutaneous Injection 3.6 mg General use-results survey (all-case survey) -Mobilization and collection of Hematopoietic Stem Cells into Peripheral Blood for Allogeneic Blood Stem Cell Transplantation- - G-Lasta (pegfilgrastim) Subcutaneous Injection 3.6 mg General use-results survey (all-case survey) -Mobilization and collection of Hematopoietic Stem Cells into Peripheral Blood for Allogeneic Blood Stem Cell Transplantation
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- Other
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •-The contract with the facility has not been concluded -Outside the contract period with the facility -Peripheral blood stem cell collection using a daily G-CSF other than pegfilgrastim* *Registration is possible if peripheral blood stem cell collection was performed using a daily G-CSF other than pegfilgrastim in the past. -This is not the first time to collect peripheral blood stem cells by administration of pegfilgrastim -Duplicate registration (already registered)
研究者
相似试验
进行中（未招募）
不适用
Subcutanoeus Delivery of Filgrastim (rG-CSF) for the Promotion of Collateral Growth in Patients with Coroanry Artery Disease (FILCAD) - FILCADCoronary Artery DiseaseEUCTR2004-003784-68-SEniversity Hospital Bern60
招募中
不适用
HEMLIBRA Subcutaneous Injection, General drug use-results survey - Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia ARoutine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with acquired hemophilia AJPRN-UMIN000048156Chugai Pharmaceutical Co. Ltd.150
招募中
不适用
HEMLIBRA Subcutaneous injection General Drug Use Surveillance(in Hemophilia A with Inhibitors).Hemophilia AJPRN-UMIN000032515Chugai Pharmaceutical Co. Ltd.100
已完成
不适用
The efficacy and safety of systemic injection of Ginkgo biloba extract, EGb761, in idiopathic sudden sensorineural hearing loss: a randomized placebo-controlled clinical trialDiseases of the ear and mastoid processKCT0001381Yuyu Phama60
进行中（未招募）
1 期
Dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetesMedDRA version: 19.0 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861Diabetes Mellitus, Type 2EUCTR2014-003196-39-GBovo Nordisk A/S705